Literature DB >> 9166833

Prognostic significance of fluorescence intensity of surface marker expression in childhood B-precursor acute lymphoblastic leukemia. A Pediatric Oncology Group Study.

M J Borowitz1, J Shuster, A J Carroll, M Nash, A T Look, B Camitta, D Mahoney, S J Lauer, D J Pullen.   

Abstract

This report describes the prognostic significance of the intensity of surface membrane antigen expression in a series of 1,231 children older than 1 year with newly diagnosed B-precursor acute lymphoblastic leukemia (ALL) treated on Pediatric Oncology Group (POG) treatment protocols. All patients had dual-color flow cytometric immunophenotyping performed at a central reference laboratory with a standard panel of monoclonal antibodies. The flow cytometers used in the study were calibrated with a standard fluorescence microparticle that permitted conversion of relative fluorescence channels to standard units of mean equivalents of soluble fluorochrome (MESF). In univariate analysis, fluorescence intensity of CD45 and CD20 was significantly associated with event-free survival (EFS), whereas other markers showed no significant correlation with outcome. Patients whose blasts were greater than the 75th percentile of intensity for CD45 (corresponding to 18,000 MESF units with CD45-FITC, or about 8% of the intensity of normal lymphocytes) fared significantly worse than those with lower-density CD45, and those whose blasts were greater than the 25th percentile of intensity for CD20 (corresponding to 17,900 MESF units with CD20-PE) had a poorer EFS. The intensity of both CD45 and CD20 was independently correlated with outcome. There was no significant correlation between intensity of expression of either antigen and traditional clinical risk factors, ploidy, or t(9;22) or t(1;19). All patients with t(4;11) had CD45 intensity greater than the 75th percentile, but CD45 intensity retained its prognostic significance after adjusting for t(4;11). In multivariate analysis, both CD45 intensity greater than the 75th percentile and CD20 intensity greater than the 25th percentile were significantly correlated with poor outcome independently of previously reported poor prognostic factors including National Cancer Institute (NCI) risk group, ploidy, trisomies of 4 and 10, and adverse translocations including t(1;19), t(9;22), and t(4;11). We conclude that in childhood B-precursor ALL, the intensity of expression of CD20 and CD45 provides prognostic information not available from simple consideration of antigen expression as positive or negative, and adds to that obtained from traditional clinical and biologic risk factors.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9166833

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  34 in total

1.  Development of T-leukaemias in CD45 tyrosine phosphatase-deficient mutant lck mice.

Authors:  M Baker; J Gamble; R Tooze; D Higgins; F T Yang; P C O'Brien; N Coleman; S Pingel; M Turner; D R Alexander
Journal:  EMBO J       Date:  2000-09-01       Impact factor: 11.598

2.  A new primary effusion lymphoma-derived cell line yields a highly infectious Kaposi's sarcoma herpesvirus-containing supernatant.

Authors:  J S Cannon; D Ciufo; A L Hawkins; C A Griffin; M J Borowitz; G S Hayward; R F Ambinder
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

3.  Allogeneic hematopoietic cell transplantation with full-intensity conditioning for adult acute lymphoblastic leukemia: results from a single center, 1998-2006.

Authors:  Kristine Doney; Ted A Gooley; H Joachim Deeg; Mary E D Flowers; Rainer Storb; Frederick R Appelbaum
Journal:  Biol Blood Marrow Transplant       Date:  2010-12-21       Impact factor: 5.742

4.  Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia.

Authors:  Deborah A Thomas; Susan O'Brien; Jeffrey L Jorgensen; Jorge Cortes; Stefan Faderl; Guillermo Garcia-Manero; Srdan Verstovsek; Charles Koller; Sherry Pierce; Yang Huh; William Wierda; Michael J Keating; Hagop M Kantarjian
Journal:  Blood       Date:  2008-08-14       Impact factor: 22.113

5.  Prognostic relevance of CD20 in adult B-cell precursor acute lymphoblastic leukemia.

Authors:  Hong Chang; Allan Jiang; Joseph Brandwein
Journal:  Haematologica       Date:  2010-01-27       Impact factor: 9.941

6.  High levels of CD20 expression predict good prognosis in chronic lymphocytic leukemia.

Authors:  Cheng Fang; Yun Zhuang; Li Wang; Lei Fan; Yu-Jie Wu; Run Zhang; Zhi-Jian Zou; Li-Na Zhang; Shu Yang; Wei Xu; Jian-Yong Li
Journal:  Cancer Sci       Date:  2013-06-07       Impact factor: 6.716

7.  In situ trans ligands of CD22 identified by glycan-protein photocross-linking-enabled proteomics.

Authors:  T N C Ramya; Eranthie Weerapana; Lujian Liao; Ying Zeng; Hiroaki Tateno; Liang Liao; John R Yates; Benjamin F Cravatt; James C Paulson
Journal:  Mol Cell Proteomics       Date:  2010-02-19       Impact factor: 5.911

8.  Flow cytometric analysis of de novo acute lymphoblastic leukemia in childhood: report from the Japanese Pediatric Leukemia/Lymphoma Study Group.

Authors:  Shotaro Iwamoto; Takao Deguchi; Hideaki Ohta; Nobutaka Kiyokawa; Masahito Tsurusawa; Tomomi Yamada; Kozo Takase; Junichiro Fujimoto; Ryoji Hanada; Hiroki Hori; Keizo Horibe; Yoshihiro Komada
Journal:  Int J Hematol       Date:  2011-07-30       Impact factor: 2.490

9.  Expression of CD20 in B Cell Precursor Acute Lymphoblastic Leukemia.

Authors:  Jeevan Kumar; Afaq Ahmad Khan; Amrita Saraf; Manorama Bhargava
Journal:  Indian J Hematol Blood Transfus       Date:  2012-12-06       Impact factor: 0.900

10.  Adverse prognostic significance of CD20 expression in adults with Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia.

Authors:  Sébastien Maury; Françoise Huguet; Thibaut Leguay; Francis Lacombe; Marc Maynadié; Sandrine Girard; Adrienne de Labarthe; Emilienne Kuhlein; Emmanuel Raffoux; Xavier Thomas; Patrice Chevallier; Agnès Buzyn; André Delannoy; Yves Chalandon; Jean-Paul Vernant; Philippe Rousselot; Elizabeth Macintyre; Norbert Ifrah; Hervé Dombret; Marie-Christine Béné
Journal:  Haematologica       Date:  2009-09-22       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.